Evidence mapPaperPMID 41359142Full record

ReviewDiscover nano2025

Nanotechnology in COVID-19 prevention, diagnosis, and treatment: a comprehensive review.

Mamo Dikamu, Yonas Syraji, Jeyaramraja Pr, Gobikanila K, Ali Raza, Dessie Ezez

Abstract readReview
In one paragraph

Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mamo DikamuDepartment of Chemistry, College of Natural Sciences, Arba Minch University, P.O. Box 21, Arba Minch, Ethiopia.
Yonas SyrajiDepartment of Biology, College of Natural Sciences, Arba Minch University, P.O. Box 21, Arba Minch, Ethiopia. yonas.syraji@amu.edu.et.
Jeyaramraja PrPG and Research Department of Botany, PSG College of Arts & Science, Civil Aerodrome Post, Coimbatore, 641014, India. jeyaramrajapr@psgcas.ac.in.
Gobikanila KPG and Research Department of Botany, PSG College of Arts & Science, Civil Aerodrome Post, Coimbatore, 641014, India.
Ali RazaDepartment of Criminal Justice, College of Professional Studies, Bowie State University, Bowie, MD, 20715, USA.
Dessie EzezDepartment of Chemistry, College of Natural Sciences, Arba Minch University, P.O. Box 21, Arba Minch, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The worst of the COVID-19 (coronavirus disease 2019) pandemic may be over, but its impact continues to be felt worldwide. During the outbreak, medical regulatory authorities introduced several principles for outbreak control, with the World Health Organization emphasizing three key strategies: prevention, early detection, and treatment. In this context, technological advancements have played a critical role, particularly nanotechnology, which has emerged as a promising platform for medical innovation. Its applications span multiple sectors, including healthcare, environmental protection, and diagnostics. These applications offer unmatched potential to enhance personal protective equipment, develop antiviral surface coatings, and engineer rapid point-of-care diagnostics. Nanotechnology contributed significantly to combating COVID-19, enhancing prevention through nanofiber-enhanced masks and nanoparticle-based disinfectants; facilitating diagnosis via gold nanoparticles (AuNPs) and magnetic nanoparticle biosensors, quantum dots, and artificial intelligence-integrated nanosensors; and supporting treatment efforts through lipid nanoparticle (LNP) vaccines, virus-like particles, and targeted drug delivery systems. We highlight key nanomaterials such as silver nanoparticles, copper nanoparticles, AuNPs, zinc oxide nanoparticles, and selenium nanoparticles, alongside advanced formulations like LNPs and polymeric nanocarriers, exploring their mechanisms of viral inactivation, sensitive detection, and controlled delivery of therapeutics. Furthermore, this review addresses critical regulatory and translational challenges and post-pandemic adaptations of nanotechnologies for emerging viral threats.

Indexed as

COVID-19NanotechnologyNanovaccinesPreventionTreatment

Identifiers

PMID41359142
PMCPMC12686313

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.